Eslicarbazepine Acetate tablets
Pre-clinicalCompleted 2 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Partial Onset Seizures
Conditions
Partial Onset Seizures
Trial Timeline
Apr 1, 2012 → Jun 1, 2014
NCT ID
NCT01830400About Eslicarbazepine Acetate tablets
Eslicarbazepine Acetate tablets is a pre-clinical stage product being developed by Eisai for Partial Onset Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT01830400. Target conditions include Partial Onset Seizures.
What happened to similar drugs?
18 of 20 similar drugs in Partial Onset Seizures were approved
Approved (18) Terminated (5) Active (2)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01830400 | Pre-clinical | Completed |
Competing Products
20 competing products in Partial Onset Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2007 | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| perampanel + perampanel | Eisai | Phase 1 | 29 |
| perampanel + perampanel + perampanel + Placebo | Eisai | Phase 3 | 40 |
| Perampanel + Placebo | Eisai | Approved | 35 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 29 |
| perampanel | Eisai | Phase 2 | 35 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| zonisamide | Eisai | Pre-clinical | 26 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 40 |
| Perampanel + Placebo | Eisai | Phase 3 | 40 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 40 |
| Adjunctive Zonisamide + Replacement with Zonisamide | Eisai | Approved | 43 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Rufinamide | Eisai | Phase 3 | 32 |
| Zonisamide | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |